NHS Corby Clinical Commissioning Group Kettering Ge
NHS Nene Clinical Commissioning Group Northampton General Hospital NHS Trust Northamptonshire Healthcare NHS Foundation Trust
NORTHAMPTONSHIRE PRESCRIBING ADVISORY GROUP
(Advising Medical, Pharmacy Practitioners and Non-Medical Prescribers
Summary of Recommendations from meeting on Weds 5th February 2014 Lubiprostone (Amitza)
Further to the last meeting and following input from gastroenterology NPAG categorised lubiprostone as double red. Meningitis Group B vaccine (Bexsero)
This is a new vaccine for the immunisation of individuals from 2 months and older against invasive meningococcal disease caused by Neisseria meningitidis group B. This vaccine has not yet been included in the national vaccination program and was therefore categorised as double red. Sayana Press (Medroxyprogesterone Acetate)
Sayana Press is a new subcutaneous long-acting contraceptive. NPAG agreed that this may offer some potential advantages over the intramuscular Depo Provera for some women and categorised it green. Colestilan (BindRen)
Colestilan is a non-absorbed, non-calcium, non-metallic phosphate-binding polymer licensed for treatment of hyperphosphataemia in adult patients with CKD stage 5 receiving haemodialysis or peritoneal dialysis. NPAG categorised Colestilan grey pending a nephrology opinion. Breakyl (fentanyl citrate)
Breakyl is licensed for the treatment of breakthrough pain in adults with cancer who are already receiving maintenance opioid therapy for chronic cancer pain. NPAG could not see a place for this product above the current choices for breakthrough pain and categorised Breakyl as double red. Gelclair (Polyvinylpyrrolidine/Hyaluronic Acid)
Gelclair sachets contain a non-pharmacological adherent gel marketed to relieve the pain of oral mucositis. NPAG categorised Gelclair as grey pending a specialist opinion. Alogliptin (Vipidia)
Alogliptin is the 5th D-PP4 inhibitor to market and is licensed for adults aged 18 and over with type 2 diabetes, in combination with other glucose lowering products including insulin. It is up to 20% less expensive than other D-PP4 inhibitors. NPAG categorised alogliptin as green. Lomitapide (Lojuxta)
Lomitapide is a novel microsomal triglyceride transfer protein inhibitor, which reduces both plasma LDL and triglycerides. It is licensed in adult patients with homozygous familial hypercholesterolaemia; an extremely rare condition. This drug falls under the auspices of Specialised Commissioning who are developing a commissioning policy; in the meantime Individual Funding Requests will be considered. NPAG categorised lomitapide as double red (IFR only). Relvar Ellipta (fluticasone furoate / vilanterol)
This is a new ICS/LABA combination inhaler licensed for the treatment of asthma and COPD. There are a number of new inhalers coming to the market in the next few months and the Northamptonshire asthma and COPD guidelines are currently under review. NPAG categorised Relvar Ellipta as grey pending these guideline updates. A2A Spacer device
This is a new small spacer device which is 14% cheaper than the Aerochamber and is available with a small or medium mask. NPAG categorised the A2A spacer as green. GeloRevoice NPAG categorised GeloRevoice throat lozenges as double red. Mirabegron shared care letter
This is now finalised and is available on Pathfinder. GPs should note that the first 3 months’ prescribing, monitoring and review must be done in secondary care before prescribing is transferred.
Rivaroxaban for DVT and PE
The local implementation guidance for NICE TA 261 has been revised to include TA 287 and is now available on Pathfinder.
Further information or clinical trial data may be obtained from the PCT Prescribing Advisers or Hospital Medicines Information Service.
Information in this bulletin is believed to be true and accurate. The NHS Northamptonshire and their employees accept no liability for loss of any nature, to persons, organisations or institutions that may arise as a result of any errors or omissions.
The copper IUD for emergency contraception, a neglected optionIt can be argued that the most important failing of modernof contraception with every client, those seeking EC deservefamily planning is the persistent epidemic of unintendedinformation on the major options: oral levonorgestrel orpregnancy. In developing countries, about 75 millionulipristal and the copper IUD. In fact, withho
ONCOLOGY CLINICAL RESEARCH TRIALS -2009 A Randomized, double blind, Placebo-Controlled Phase III trial for Postmenopausal Women with ER, PgR+ Advanced Breast CA.With or without Inhibition of EGF & Her2 Growth Factor Receptors;Neo-Adjuvant Phase III study comparing 16-18 wks of neoadjuvant Exemestane, Letrozole. Or Anastrozole. Postmenopausal Stage II & III ER A Randomized Phase I